News – Page 34 – Alligator Bioscience

2017-11-07

Regulatory

Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013

Lund, Sweden, 7 November 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceut ...

2017-10-25

Regulatory

Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...

2017-10-24

Regulatory

ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...

2017-09-21

Regulatory

Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2017-09-13

Regulatory

Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...

2017-08-23

Regulatory

“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...

2017-08-17

Regulatory

Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...

2017-08-07

Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing tumor-directed immunotherapies for canc ...

2017-07-21

Regulatory

Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...